Home>Topics>>Lucrative Opportunities In Amarin's Options Market
Lucrative Opportunities In Amarin's Options Market
Healthcare Sector and Stocks Analysis from Seeking Alpha
Mon, 26 Nov 2012
By Brian L. Wilson : Although the arguments between Amarin (NASDAQ: AMRN ) bulls and bears are starting to become quite stale due to a lack of information about the NCE (New Chemical Entity) status of their flagship drug Vascepa from the FDA (many months after approval, which is rare). There is ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.